Lipella 的新药在治疗口腔扁平苔藓方面显示出前景，导致股票大幅飙升。 Lipella's new drug shows promise in treating oral lichen planus, leading to a significant stock surge.

Lipella制药公司报告说,LP 310试验成功,LP 310试验结果,一种治疗口服衣原体的药物,显示疼痛、炎症和溃疡有显著改善,没有严重的副作用。 Lipella Pharmaceuticals has reported successful Phase 2a trial results for LP-310, a drug treating oral lichen planus, showing significant improvements in pain, inflammation, and ulceration with no serious side effects. 宣布之后,公司股票在市场前贸易中猛涨65%以上。 The company's stock surged over 65% in pre-market trading following the announcement. 目前正在进一步进行剂量较高的试验。 Further trials with higher doses are ongoing.